AUG 27, 2019 9:00 AM PDT

Akoya Biosciences Webinar Series: Comprehensive Meta-analysis of Biomarker Technologies for Predictive Response of PD-1/PD-L1 Checkpoint Therapies

Sponsored by: Akoya Biosciences
C.E. Credits: P.A.C.E. CE Florida CE
  • Vice President, Translational and Scientific Affairs, Akoya Biosciences
      Dr. Cliff Hoyt is the Vice President of Translational and Scientific Affairs, having joined Akoya Bio through the acquisition of the Phenoptics business from Perkin-Elmer. Previously, Cliff was co-founder and CTO of CRI, Inc., acquired by PerkinElmer in 2011. Since then, as Oncology Fellow, Cliff lead development of multiplexed staining methods (Opal), built the contract research business, partnered with pharma and academia to understand translational research and clinical needs and to advance adoption of multiplexed immunofluorescence methods, and worked with PKI business leaders to develop an oncology translational strategy. Cliff has been Principal Investigator on NIH SBIR grants, received his BA in Physics from Williams College in 1983 and MS in Mechanical Engineering from MIT in 1987, and is named inventor on over 20 patents.
    • MD/PhD candidate, John Hopkins University School of Medicine
        Steve Lu is currently enrolled in the Medical Scientist Training Program (MD/PhD) at Johns Hopkins University School of Medicine where I am working on my PhD degree in Cellular and Molecular Medicine. Graduated from college from University of Texas at Austin with degrees in Biology and Biochemistry where I researched on DNA repair and carcinogenesis.

        Mr. Lu's current research focuses on cancer genetics and immunotherapies in the context of skin cancers and mismatch repair-deficient tumors. More specifically, my research uses genomics and multi parametric assays to understand the mechanisms that tumors use to evade the immune system. The goal is to lead to improved patient selection for therapies and to identify additional pathways that can be targeted.

      DATE:  August 27, 2019 
      TIME:  9:00am PDT, 12:00pm EDT
      Immunotherapies targeting the PD-1/PD-L1 interaction have proven remarkably effective for treating cancer in some patients. There has now been considerable focus into the sensitivity and specificity measures of the technologies used to predict clinical response and aid in better patient selection. Recently, researchers at Johns Hopkins School of Medicine published a comprehensive comparison in JAMA Oncology to determine the relative accuracy of these biomarker assays including PD-L1 immunohistochemistry (IHC), multiplexed immunofluoresence (mIF) and genomic approaches including tumor mutational burden (TMB) and gene expression profiling (GEP). Steve Lu, of Johns Hopkins School of Medicine will present the study results demonstrating the improved predictive value of multiplexed IHC/IF methods compared to other modalities. The review compared results of over 8000 patients from over 45 published studies detailing the treatment selection across multiple types of lung, bladder, skin, and gastric amongst other cancers. Statistical analysis of the different methods suggest multiplexed IHC/IF biomarker strategies are associated with improved predictive performance over PD-L1 IHC, TMB or GEP approaches alone.
      Learning Objectives:
      • Comparative predictive metrics across multiple biomarker technologies for predicting PD-1/PD-L1 therapies
      • Importance of quantitative protein measurements of immune cell subsets and impact of spatial arrangements in disease states
      • Latest advances in multiplexed immunofluorescent methods for robust, high throughput clinical research.
      Webinars will be available for unlimited on-demand viewing after live event.

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

      Show Resources
      Show Resources
      Connect with us